Simulations Plus (NASDAQ:SLP) Trading Down 4.2% – Time to Sell?

Simulations Plus, Inc. (NASDAQ:SLP) traded down 4.2% on Tuesday . The company traded as low as $33.01 and last traded at $32.74. 53,890 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 188,230 shares. The stock had previously closed at $34.16.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp increased their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Finally, StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.40.

Simulations Plus Trading Down 4.8 %

The company has a 50 day moving average of $28.84 and a 200-day moving average of $30.04. The firm has a market capitalization of $654.21 million, a P/E ratio of 81.33 and a beta of 1.13.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The business had revenue of $22.43 million for the quarter, compared to analyst estimates of $21.93 million. During the same period last year, the firm earned $0.20 earnings per share. Simulations Plus’s revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the sale, the director now owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 19.40% of the stock is owned by insiders.

Institutional Trading of Simulations Plus

Several large investors have recently bought and sold shares of SLP. Jones Financial Companies Lllp boosted its stake in shares of Simulations Plus by 53.6% in the 4th quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after purchasing an additional 427 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Simulations Plus during the fourth quarter worth $39,000. Tower Research Capital LLC TRC lifted its stake in shares of Simulations Plus by 42.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after acquiring an additional 764 shares during the last quarter. AlphaQuest LLC boosted its holdings in shares of Simulations Plus by 502.9% during the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock valued at $75,000 after acquiring an additional 2,243 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in Simulations Plus during the 4th quarter worth $86,000. 78.08% of the stock is owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.